Production (Stage)
Adverum Biotechnologies, Inc.
ADVM
$2.21
-$0.02-0.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -72.22% | -72.22% | -100.00% | -100.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -72.22% | -72.22% | -100.00% | -100.00% |
| Cost of Revenue | 25.81% | -0.57% | -17.94% | -20.56% | -23.31% |
| Gross Profit | -24.42% | -2.92% | 15.48% | 17.09% | 20.24% |
| SG&A Expenses | 26.93% | 18.93% | -8.97% | -7.18% | 7.11% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 26.30% | 7.53% | -14.67% | -15.58% | -12.41% |
| Operating Income | -25.52% | -9.75% | 13.03% | 13.30% | 10.19% |
| Income Before Tax | -26.26% | -8.19% | 18.68% | 18.80% | 16.70% |
| Income Tax Expenses | -- | -- | -1,631.08% | -1,608.11% | -1,620.83% |
| Earnings from Continuing Operations | -27.41% | -9.15% | 19.63% | 19.68% | 17.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -27.41% | -9.15% | 19.63% | 19.68% | 17.49% |
| EBIT | -25.52% | -9.75% | 13.03% | 13.30% | 10.19% |
| EBITDA | -27.96% | -11.82% | 11.65% | 12.29% | 9.48% |
| EPS Basic | 32.54% | 44.44% | 46.91% | 35.34% | 25.74% |
| Normalized Basic EPS | 33.20% | 44.92% | 43.83% | 32.02% | 21.28% |
| EPS Diluted | 32.54% | 44.44% | 46.91% | 35.34% | 25.74% |
| Normalized Diluted EPS | 33.20% | 44.92% | 43.83% | 32.02% | 21.28% |
| Average Basic Shares Outstanding | 78.64% | 96.15% | 69.97% | 43.71% | 17.33% |
| Average Diluted Shares Outstanding | 78.64% | 96.15% | 69.97% | 43.71% | 17.33% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |